Literature DB >> 20601920

B7-H1 expression in vestibular schwannomas.

David J Archibald1, Brian A Neff, Stephen G Voss, Patrick L Splinter, Colin L W Driscoll, Michael J Link, Haidong Dong, Eugene D Kwon.   

Abstract

HYPOTHESIS: B7-H1 is expressed in vestibular schwannomas.
BACKGROUND: Little is known about how benign human vestibular schwannomas interact with antibody-mediated or cell-mediated immunity. We report on the aberrant expression of a novel T-cell coregulatory molecule, B7 homolog 1 (B7-H1), in vestibular schwannomas and discuss the implications of B7-H1 expression and tumor aggressiveness and a potential regulator of B7-H1 expression.
METHODS: Immunohistochemical staining for B7-H1, CD8+, CD3+, and CD4+ lymphocytes were performed on 48 fresh-frozen vestibular schwannoma tissue specimens. A clinical review of patient presenting symptoms and tumor characteristics was performed. Real-time polymerase chain reaction was used to determine if there was differential expression of B7-H1 messenger RNA and microRNA-513, a known regulator of B7-H1, in several strongly positive and negative B7-H1 vestibular schwannomas.
RESULTS: Nine (19%) of 48 tumors were negative, 23 (48%) tumors were 1+ mildly positive (<20% section area), and 16 (33%) stained 2+ strongly positive (>or=20% section area) for B7-H1. The average number of CD8 cells per high-power field was 2.1 for positive-staining tumors and 1.0 for negative tumors (p = 0.16). Failure of tumor control with stereotactic radiation (p = 0.029) was significantly greater in the strongly positive B7-H1 tumors. Real-time polymerase chain reaction did not show significant differential expression of microRNA-513 (p = 0.62) or B7-H1 messenger RNA (p = 0.35) between the tumors showing strong and negative immunohistochemical staining for B7-H1 protein.
CONCLUSION: Vestibular schwannoma tumors express B7-H1, which has been associated with immune tolerance and adverse disease characteristics in several malignancies. Growing tumors that were surgically removed after failed stereotactic radiation therapy were significantly more likely to strongly express B7-H1 protein, which lends some credibility to the hypothesis that immuno-evasion may play some role in their continued growth. Although clinical trends were seen, greater statistical power is required to evaluate whether B7-H1 expression correlates with more aggressive tumor growth or poorer hearing class. B7-H1 seems to be expressed in equal amounts at the RNA level in all vestibular schwannoma tumors that suggests that differential protein expression is occurring at the posttranscriptional level. However, microRNA-513 does not regulate B7-H1 protein expression in these tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20601920      PMCID: PMC4810681          DOI: 10.1097/MAO.0b013e3181e40e4f

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  23 in total

Review 1.  Radiobiology, principle and technique of radiosurgery.

Authors:  Ajay Niranjan; John C Flickinger
Journal:  Prog Neurol Surg       Date:  2008

Review 2.  Immunoregulatory role of B7-H1 in chronicity of inflammatory responses.

Authors:  Haidong Dong; Xianming Chen
Journal:  Cell Mol Immunol       Date:  2006-06       Impact factor: 11.530

3.  Disease progression in sporadic inclusion body myositis: observations in 78 patients.

Authors:  A Peng; B M Koffman; J D Malley; M C Dalakas
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

4.  Schwannoma cells induce a tumor-cell-specific cytotoxic-T-cell response upon transplantation into syngeneic rats but escape elimination through the secretion of immunosuppressive factors.

Authors:  U Altenschmidt; R Kahl; E Klundt; E Stöcklin; M Mihatsch; K Weindel; B Groner
Journal:  Int J Cancer       Date:  1997-03-04       Impact factor: 7.396

5.  The interaction mode of premalignant Schwann and immune effector cells during chemically induced carcinogenesis in the rat peripheral nervous system is strongly influenced by genetic background.

Authors:  Katharina M Gering; Judith A M Marx; Klaus Lennartz; Christine Fischer; Manfred F Rajewsky; Andrea Kindler-Röhrborn
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

Review 6.  B7-H1 pathway and its role in the evasion of tumor immunity.

Authors:  Haidong Dong; Lieping Chen
Journal:  J Mol Med (Berl)       Date:  2003-04-30       Impact factor: 4.599

7.  Immunologic detection of acoustic neuroma: preliminary report.

Authors:  L A Harker; J Nysather; A Katz
Journal:  Laryngoscope       Date:  1978-05       Impact factor: 3.325

8.  MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.

Authors:  Tyler E Miller; Kalpana Ghoshal; Bhuvaneswari Ramaswamy; Satavisha Roy; Jharna Datta; Charles L Shapiro; Samson Jacob; Sarmila Majumder
Journal:  J Biol Chem       Date:  2008-08-15       Impact factor: 5.157

9.  Cryptosporidium parvum induces B7-H1 expression in cholangiocytes by down-regulating microRNA-513.

Authors:  Ai-Yu Gong; Rui Zhou; Guoku Hu; Jun Liu; Danuta Sosnowska; Kristen M Drescher; Haidong Dong; Xian-Ming Chen
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

10.  MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes.

Authors:  Ai-Yu Gong; Rui Zhou; Guoku Hu; Xiaoqing Li; Patrick L Splinter; Steven P O'Hara; Nicholas F LaRusso; Garrett A Soukup; Haidong Dong; Xian-Ming Chen
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

View more
  9 in total

1.  Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.

Authors:  Shiyang Wang; Benjamin Liechty; Seema Patel; Jeffrey S Weber; Travis J Hollmann; Matija Snuderl; Matthias A Karajannis
Journal:  J Neurooncol       Date:  2018-02-09       Impact factor: 4.130

2.  Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.

Authors:  Shingo Inaguma; Zengfeng Wang; Jerzy Lasota; Maarit Sarlomo-Rikala; Peter A McCue; Hiroshi Ikeda; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2016-08       Impact factor: 6.394

3.  Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.

Authors:  Sonam Dilwali; Martijn C Briët; Shyan-Yuan Kao; Takeshi Fujita; Lukas D Landegger; Michael P Platt; Konstantina M Stankovic
Journal:  Mol Oncol       Date:  2015-03-31       Impact factor: 6.603

4.  A Unified Methodological Framework for Vestibular Schwannoma Research.

Authors:  Lukas D Landegger; Jessica E Sagers; Sonam Dilwali; Takeshi Fujita; Mehmet I Sahin; Konstantina M Stankovic
Journal:  J Vis Exp       Date:  2017-06-20       Impact factor: 1.355

Review 5.  Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment.

Authors:  Cathal J Hannan; Daniel Lewis; Claire O'Leary; Carmine A Donofrio; Dafydd G Evans; Emma Stapleton; Simon R Freeman; Simon K Lloyd; Scott A Rutherford; Charlotte Hammerbeck-Ward; David Brough; Stuart M Allan; David Coope; Andrew T King; Omar N Pathmanaban
Journal:  J Neurol Surg B Skull Base       Date:  2020-09-10

6.  The molecular biology of vestibular schwannomas and its association with hearing loss: a review.

Authors:  Erika Celis-Aguilar; Luis Lassaletta; Miguel Torres-Martín; F Yuri Rodrigues; Manuel Nistal; Javier S Castresana; Javier Gavilan; Juan A Rey
Journal:  Genet Res Int       Date:  2012-02-20

7.  Identifying predictors of early growth response and adverse radiation effects of vestibular schwannomas to radiosurgery.

Authors:  Soroush Larjani; Eric Monsalves; Houman Pebdani; Boris Krischek; Fred Gentili; Michael Cusimano; Normand Laperriere; Caroline Hayhurst; Gelareh Zadeh
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

Review 8.  Biomarkers in Vestibular Schwannoma-Associated Hearing Loss.

Authors:  Luis Lassaletta; Miryam Calvino; Jose Manuel Morales-Puebla; Pablo Lapunzina; Lourdes Rodriguez-de la Rosa; Isabel Varela-Nieto; Victor Martinez-Glez
Journal:  Front Neurol       Date:  2019-09-18       Impact factor: 4.003

9.  Gamma Knife Radiosurgery does not alter the copy number aberration profile in sporadic vestibular schwannoma.

Authors:  Morten Lund-Johansen; Per-Morten Knappskog; Aril Løge Håvik; Ove Bruland; Dhanushan Dhayalan
Journal:  J Neurooncol       Date:  2020-09-27       Impact factor: 4.130

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.